
In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with ImmunityBio's Chief Medical Officer, Dr. Bobby Reddy, for a fascinating, hopeful look at the future of bladder cancer treatment.
They unpack how next-generation immunotherapies like ANKTIVA—paired with innovative approaches to BCG—are reshaping care for patients, especially those with limited options, while also tackling real-world challenges like ongoing BCG shortages.
Dr. Reddy breaks down the science in a way that's accessible, highlighting how activating the body's own immune system could lead to longer-lasting responses and even help patients avoid more invasive treatments. Tune in to this conversation about progress and possibility.
Flere episoder fra "Bladder Cancer Matters"



Gå ikke glip af nogen episoder af “Bladder Cancer Matters” - abonnér på podcasten med gratisapp GetPodcast.








